MIRA
INFORM REPORT
|
Report Date : |
08.11.2007 |
IDENTIFICATION
DETAILS
|
Name : |
BARRETT HODGSON PAKISTAN (PRIVATE) LTD |
|
|
|
|
Registered Office : |
F-423, S.I.T.E.,
Karachi |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Date of Incorporation : |
1992 |
|
|
|
|
Com. Reg. No.: |
0028289 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture &
Marketing of Pharmaceutical Products |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
Business Name
BARRETT HODGSON PAKISTAN (PRIVATE) LTD
Full Address
Registered Address
& Factory
F-423, S.I.T.E.,
Karachi, Pakistan
Tel 92 (21) 2570651 - 57 (7 Lines)
Fax 92 (21) 2568827, 2570650
Short Description Of Business
|
Nature of Business |
Manufacture & Marketing of Pharmaceutical Products |
|
Year Established |
1992 |
|
Registration # |
0028289 |
Branches
|
Address |
1-A, Shahid Plaza, Jinnah Avenue, Blue Area, Islamabad,
Pakistan |
|
Tel # |
92 (51) 2277098, 2270275 |
|
Fax # |
92 (51) 2270277 |
|
Address |
175, Gen. Sarfraz Khan Road, Shadman-II, Lahore, Pakistan |
|
Tel # |
92 (42) 7562711, 7562705 |
|
Fax # |
92 (42) 7582854 |
Auditors
M/s A.F. Ferguson & Company
(Chartered
Accountants)
State Life Building, 1-C, Off: I.I. Chundrigar Road, Karachi, Pakistan
Legal Status
Subject Company was established as a Private Limited Company in 1992
|
Authorized Capital |
Rs. 250,000,000/-
divided into 2,500,000 shares of Rs. 100/- each |
|
Issued & Paid up Capital |
Rs. 136,570,000/- divided
into 1,365,700 shares of Rs. 100/- each |
Details of Directors
|
Names |
Nationality |
Address |
Designation |
|
Dr. Iram Afaq Mr. Tariq Amin Dr. M.S. Habib Mr. Shahid Mansoor Dr. Hasan Tharani Mr. S. Shakeel Ahmed |
Pakistani Pakistani Pakistani Pakistani Pakistani Pakistani |
166, Khayaban-e-Shahbaz, Phase VI, DHA, Karachi House No. 34/II, Khayaban-e-Badar, Phase-V, DHA, Karachi 166, Khayaban-e-Shahbaz, Phase VI, DHA, Karachi House No. C-55, Block 9, Gulshan-e-Iqbal, Karachi B-112, Block-10, Gulshan-e-Iqbal, Karachi D/17, Askari-IV, Apartment, Rashid Minhas Road, Karachi |
Chief Executive Director Director Director Director Director |
Shareholders
|
Names |
No. of Shares |
|
Barrett Hodgson Limited, U.K. Dr. M.S. Habib Mr. Benyamin Naeem Habib Dr. Iram Afaq |
1,207,279 57,599 100,821 1 |
Associates
A. Subsidiary
None
B. Associated Companies
(1) Lahore Medical Instruments (Pvt) Limited, Pakistan.
Products
Manufacture & marketing of different pharmaceutical class
like Anti Biotic, Anti Malarials, Anti-Rheumatic, Antihistamine, Narcotic Analgesic,
Non Steroidal Respiratory Anti Inflamatory, Quinolones, Vitamins,
Phenothiazine, Hypolipidaemics, Muscle Relaxant, Amoebicide,
Calcium-Antagonist, Cardio Selective Beta Blocker with their brand names of ACICON, BAMBEC, BAYHEP, BETALOC ZOK, BETAXEN,
BINADEX, BRICANYL, CEFAMEZIN, CEFCOM, CEFIX, CEFIZOX, CEFNIR, CEFSPAN,
CIPOCAINE, CIPOTIC, DOMEL, DYNAQUIN, ERADEP, EXOCIN, FEBROL, FLUCOL, GENTICYN,
GIXER, INOCEF, INOQUIN, JECTOFER, LEVAQUIN, MOBIKARE GEL, MST CONTINUS,
MYLAXON, OCUFEN, PENGLOBE, PERSCH, PLENDIL, POLYFER, PRED FORTE, PULMICORT,
QUINTEC, RECOL, ROMICEF, SARTAN, WINTAX, XYLOAID, XYLOCAINE, ADRENALINE
Number of Employees
350
Annual Production Volume
The capacity and production of the company’s plant is
indeterminable as it is multi-product and involves varying processes of
manufacture
Annual Sales Volume
|
Year |
In Pak Rupees |
|
2006 |
500,000,000/- (Estimated) |
Agencies (Foreign)
ASTRAZENECA, U.K.
ASTELLAS DEUTSCHLAND GMBH, GERMANY.
MIKA PHARMA GMBH, GERMANY.
ALLERGAN, U.S.A.
ZHEJIANG JINGXIN PHARMACEUTICAL IMPORT & EXPORT, CHINA.
Distributors
More than 80 Distributors in all over Pakistan
Exporting Countries
Mainly to Asian, Middle East and European Countries
Bankers
Faysal Bank Limited, Pakistan.
Habib Bank Limited, Pakistan.
Habib Metropolitan Bank Limited, Pakistan.
Standard Chartered Bank, Pakistan.
Saudi Pak Commercial Bank Limited, Pakistan.
ABN AMRO Bank, Pakistan.
Memberships
Pakistan Pharmaceutical Manufacturers Associations.(PPMA)
Karachi Chamber of Commerce & Industry.(KCCI)
Foreign Exchange Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 60.88 |
|
UK Pound |
1 |
Rs. 127.80 |
|
Euro |
1 |
Rs. 89.20 |
Comments
Subject Company was established in 1992 and is engaged in manufacturing & marketing of Pharmaceutical Products. Market reputation is extremely good. Directors are reported as resourceful and experienced professionals. Trade relations are reported as fair. The Company can be considered for normal business dealings at usual trade terms and conditions.
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)